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ABSTRACT 
In situ gelling systems are better and formulation of time since they have multiple advantages over conventional drug delivery system includes 
better bioavailability, retention on the desired site and patient compliance. Nasal drug delivery is a better option to deliver drug across Blood 
brain barrier and in this research work an attempt was made to prepare in-situ temperature triggered nasal gel of Sumatriptan Succinate for 
the treatment of Migraine. For the preparation of best insitu gel Poloxamer 188 in different concentration was used to formulate insitu gel along 
with HPMC K4M  .The optimized formulation was chosen after evaluating the prepared gel for pH, Viscosity, Gel strength  and mucoadhesive 
strength then final optimized formulation was subjected for texture analysis, in vitro drug release and Differential Scanning Calorimetery and 
drug release data was also evaluated for Release kinetic of formulation .Formulation batch F5 was selected as best formulatio n batch because it 
exhibited best result among all the prepared formulation and proved as promising  temperature triggered formulation of in-situ gel. 
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1. INTRODUCTION  
In Ayurveda system of medicine the intranasal therapy is 
accepted form of treatment. It is also called “NASAYA 
KARMA”. Nasal route has improved systemic bioavailability 
and it achieves fast and higher level of drug absorption as 
compared to oral. Nasal route is good because it is more 
permeable to compounds than gastro intestinal tract due to 
insufficiency of pancreatic and gastric enzymatic activity, 
neutral pH of nasal mucus. 1 
In nasal drug delivery formulation, gel formulation is very 
famous in pharmaceutical researchers. Gel formulation can 
keep on any application area more longer time than solution 
due to the imparted viscosity. 
A delivery system in which solution is changed in to the gel 
(sol-gel) by changing temperature can keep longer onto 
mucosal epithelium. This type of system is turned as in-situ 
gelling drug delivery. Ropinirole, Midazolam are best 
example of In-situ nasal thermo-responsive gel drug delivery 
system. The noninvasiveness and self-administration nature 
also attracts the formulation and it helps scientists to deliver 
peptide and protein components. 2-3 
The first step in absorption of drug from the nasal cavity is 
passage through the mucus. Small, unchanged drug easily 
pass through this layer. So many absorption mechanism 
were established earlier but only two mechanism have been 
mostly used such as 4  
First mechanism It is an aqueous route of transport, it is slow 
and inactive. It is known as paracellular process. (transport 
of substances across an epithelium by passing through the 
intercellular space)Drugs having molecular weight greater 
than 1000 Daltons shows poor bioavailability.  
Second Mechanism It involves lipid route of transport. It is 
known as the transcellular process. Transportation of solutes 
by a cell through a cell. It is liable for the transport of 
lipophilic drugs that show a rate dependence on their 
lipophillicity. Drug molecules also cross cell membranes by 
an active transport route via carrier-mediated mean. 5 
There are dismal statistics that indicate that migraines are 
quite common. 25-30% of women and 15-20% of men 
occasionally get migraines. It is of two major types-Classical 
migraine (migraine with aura) - headache is preceded by 
visual or other neurological symptoms. Common migraine 
(migraine without aura) - it is not accompanied any visual 
symptoms.6-7 
Sumatriptan Succinate is an effective drug in the treatment of 
Migraine patients. Sumatriptan Succinate is a selective 5HT-
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receptor agonist structurally similar to Serotonin. The 
specific receptor subtype (5-HT 1D and 5-HT 1B) it activates, 
are present on the cranial arteries and veins. Acting as an 
agonist at these receptors, Sumatriptan reduces the vascular 
inflammation associated with migraine. 8 
Administration of conventional tablets of Sumatriptan 
Succinate has been reported to exhibit very low 
bioavailability, presystemic metabolism, and incomplete 
absorption from stomach as well as irritation caused at the 
site of injection. For a good therapeutic response and 
improve patience compliance. It was the objective of the 
study to develop a dosage form ‘‘Nasal in-situ Gel’’ of the drug 
Sumatriptan Succinate using polymers like Poloxamer, 
HPMC, which will avoid the metabolism of the drug in GIT 
and may increase the bioavailability by increasing 
concentration of drug at a site of action. A research article on 
development of immediate release liquid fill formulations for 
soft gels of Sumatriptan Succinate and mentioned the HPMC 
is best gelling agent with this drug as compared to pectin 9-10 
In order to improve rate of absorption and thereby its 
bioavailability. Therefore it was assumed that the application 
of drug in the form of in-situ nasal gel will be effective. 
In the present study nasal in-situ gel formulation was 
prepared over conventional tablet or other formulations, as 
it has several advantages like convenient and long term 
therapy is possible, degradation of drug in GIT is absent and 
may increase the bioavailability by increasing the 
concentration of drug at a site of action. 
2. MATERIAL AND METHODS   
Sumatriptan succinate was a gift sample from Nosch 
Laboratory Pvt. Ltd. Hyderabad. HPMC K4M, Poloxamer 188 
and Glycerin were purchased from Central Drug House and 
all other chemicals are of analytical grade.  
3 Preparation of nasal in-situ gel by temperature 
triggered method.  
Nasal in-situ gel was prepared using cold method involving 
addition of polymers and additives in cold water with 
continuous agitation. The formed mixture was stored 
overnight at 4-10ºC. Polymer (poloxamer 188 in 
concentration 4, 6, 8, 12, 14% w/v) at cold condition was 
dissolved in water. The quantity of mucoadhesive polymer 
HPMC K4M (0.5% w/v) and glycerin (0.5% w/v) were mixed 
with one by one with continuous agitation. The formed 
mixture was stored overnight at freezing condition. 
 
Table no 1: Composition of formulation batches [71] 
 
 
3.1Evaluation of Insitu Gel  
Physical appearance and clarity test: The prepared 
formulations are visually examined of any foreign particles 
present. 
3.1.1 pH of gel: pH of human nasal mucosa is found to be in 
the range of 5-6.5. But it can tolerate about 4-7.5. pH of 
prepared formulations should be within the range of nasal 
mucosa which can tolerate in order to reduce nasal 
irritation. pH of all formulations is mentioned in table 2. The 
result indicates that in all formulations pH is found to be 
within the tolerable. They are in the range of 6.1-6.5 
Table no 2: Evaluation of pH 
 
 
3.1.2 Rheological studies: Viscosity of the nasal in-situ gel 
is an important factor in determining the residence time of 
drug in nasal cavity. Viscosity was determined by using 
Brooke field Viscometer DV ΙΙ + Pro model in spindle no T95. 
The viscosity was measured using 25 mg of gel in 100ml 
beaker. The T95 bar spindle was fixed and suspended so that 
spindle does not touch the bottom of the beaker. T95 spindle 
was used for determining the viscosity. Factors like 
temperature (before and after gelation), shear force and 
sample size was maintained during this process. The T bar 
spindle was moved up and down giving viscosities at 
number of points. The rotation speed was 50 and 100 rpm to 
study the effect of shear on viscosity. The average of the 
three readings was used to calculate viscosity in cps.  
The viscosities of the formulations before and after gel 
formulation are mentioned below in table no 3 and 4. 
Table no3: Rheological studies of nasal in-situ gel before 
gelation 
Shear rate 
(rpm) 
             Viscosity(cps) 
 F1 F2 F3 F4 F5 
50 422 480 663 887 851 
100 285 320 426 710 349 
 
Table no 4: Rheological studies of nasal in-situ gel after 
gelation 
Shear rate 
(rpm) 
             Viscosity(cps) 
 F1 F2 F3 F4 F5 
50 513 645 1110 755 2073 
100 336 543 825 1075 702 
 
3.1.3 Measurement of gel strength: It is very important 
that the nasal in-situ gel formulation must have suitable gel 
strength. The gel strength of nasal gel formulation at 37ºC 
Composition (%w/v) F1 F2 F3 F4 F5 
Sumatriptan Succinate 10 10 10 10 10 
Poloxamer 188 4 6 8 12 14 
HPMC K4M 0.5 0.5 0.5 0.5 0.5 
Glycerin  0.5 0.5 0.5 0.5 0.5 
Distilled water qs qs qs qs qs 
Formulations pH 
F1 6.1 
F2 6.1 
F3 6.3 
F4 6.5 
F5 6.5 
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±1, increased as the concentration of Poloxamer 188 and 
HPMC K4M increased.  
3.1.4 Measurement of gel temperature: The gelation 
temperature was described by Miller and Donovan 
technique. In this technique phase transition occurred from 
liquid phase to a gel phase. In this 2 ml in-situ gel transferred 
to test tube and placed into water bath then the temperature 
of water bath increased slowly and constantly. Gel was 
allowed to equilibrate for 5 minutes at each setting, then the 
formulation was examined for gelation. When the meniscus 
would no longer move upon tilting to 90ºC, this is known as 
gelation temperature. 
3.1.5 Mucoadhesive strength: Mucoadhesive strength is 
known as the force to detach the in-situ gel formulation from 
nasal mucosa tissue, for determining the mucoadhesive 
strength we use modified special balance. A small section of 
nasal mucosa of goat was cut and tied on 2 glass vials with 
the help of thread and stored it at 37ºC ±2ºC for 10 minute 
and then 50mg of gel was placed on first vial and placed 
below the height adjustable balance. While on another hand 
second vial was fixed in inverted position to the underside of 
the same balance after this height both vial were adjusted 
and come in intimate contact for 5 minute to ensure the 
contact between nasal mucosal tissue and the in-situ gel 
formulation. Then weight was put off on the other side of 
balance, until vials got detached, it expressed as the strength 
or stress in weight. 
Table no 5: Mucoadhesive strength of nasal in-situ gel 
 
 
3.1.6 In-vitro drug release studies: The in-vitro drug 
release studies of the prepared in-situ gel (F5) were carried 
out in French diffusion cell. French diffusion membrane was 
used as diffusion membrane. Diffusion cell was filled with 
phosphate buffer pH7.4; diffusion membrane was mounted 
on cell. The temperature was maintained at 34-37ºC. At 
predetermined time points, 5 ml sample was withdrawn 
from receptor compartment, replaced the sample volume 
with phosphate buffer pH 7.4, after each sampling for a 
period of 360 minute. The sample withdrawn were filtered 
and analyzed for drug content by using phosphate buffer as 
blank by UV spectroscopy at 228 nm. 
Table no 6: In-vitro drug release studies 
Time (hrs) % Cumulative drug release 
1 0.555 
2 0.765 
3 0.995 
4 1.185 
5 1.435 
6 1.645 
 
Table no. 7: Regression co-efficient (r2) values of 
different kinetic models for formulation F5 
Release kinetic Model Regression value (r2) 
Zero order  0.931 
First order 0.880 
Higuchi 0.880 
Peppas 0.880 
 
3.1.7 Differential Scanning Calorimetry: 
 Instrument version: Perkin Elmer Jade DSC 
Load temperature:  30ºC 
High temperature: 330ºC 
Rate of heat flow: 10ºC/min 
DSC was used for thermal of drug, mixture and excipients. 
Individual sample of Sumatriptan Succinate (2.367 mg) was 
weighed and scanned in the temperature range of -27 -305º 
at the heating rate of 5ºC/min under an atmospheric 
condition of dry nitrogen. Thermogram obtained of all 
sample. A formulated nasal in-situ gel was also subjected to 
this procedure. 3.612 mg of sample powder of in-situ gel was 
weighted and processed for the above method for DSC. 
Thermogram was shown in graph no 5. F3 sample was also 
analyzed which is shown in Fig no -2  
 
 
Fig no.2: DSC thermogram of the Formulation 
Formulations Time (sec) Weight (gm) 
F1 35 05 
F2 36 07 
F3 40 7.6 
F4 47 8 
F5 58 10.4 
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In the thermogram of formulation glass temperature of 
polymer is visible between 50- 60°C and one more 
endotherm between 160-200°C shows melting point of drug 
into the thermogram though the intensity of peak is very less 
which shows the significant interaction between drug and 
polymer. 
 
 
Fig no-3: DSC thermogram of pure drug 
 
The thermogram of drug, an endotherm peak was observed 
between 169-190°C which is reported as melting point of 
the drug. One more endotherm peak was observed at 155°-
160C which is due to the evaporation of the bond bond 
water into drug molecule. 
 
 
Fig no-4: DSC thermogram of HPMC K4M polymer 
In this thermogram of polymer one endothermic peak was 
obtained at 50-55°C it should be glass transition of polymer 
and a sharp exothermic peak was obtained at 90°C which is 
revealed property of crystallization and freezing point of 
polymer. 
3.1.8 Texture Analysis: Texture analysis is a primary 
concerned with measurement of mechanical properties of 
nasal in-situ gel. The analyses of texture or rheological 
properties are an assessment of a particle characteristic, 
such as adhesiveness, Hardness, elasticity. Contrary to 
verbal description- sticky, tacky, gummy texture analysis 
made these rheological characteristics quantifiable and 
therefore comparable. 
Texture analysis of optimal gel was performed by using TA. 
In which pre- test speed was 0.05 mm/sec and post-test 
speed was 10.0mm/sec. The force applied was 500 gm. it 
was preformation 400 test run and a curve is obtained as a 
result of mucoadhesive force of optimized gel was 6.8 kg 
Parameters fixed for Mucoadhesive test- 
Sequence Title: Adhesive Test ,Test Mode: Tension ,Pre-Test 
Speed: 0.5 mm/sec ,Test Speed: 0.5 mm/sec ,Post-Test 
Speed: 10.0 mm/sec ,T.A. Variable No: 5: 500 ,Applied Force: 
500.0 g ,Return Distance: 10.0 mm ,T.A. Variable No: 8: 0.0 
%, Trigger Type: Auto ,Trigger Force: 5.0 g ,Probe: A/MUC; 
Mucoadhesion 
TEST RIG:  
GEL F5 AFTER HEATING, Points per second: 400 Test Run 
Mucoadhesive Overlay Curve:
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Fig no. 5: Result Avg Mucoadhesive force for 06 repetitive gel sample F5 
Table no 8: Texture analysis report of in-situ nasal gel (after heating) 
Sample 
number  
Batch  Mucoadhesive 
force (kg)  
1  Gel Sample F5-1  1.117  
2  Gel Sample F5-2  1.153  
3  Gel Sample F5-3  1.319  
4  Gel Sample F5-4  1.311  
5  Gel Sample F5-5  1.253  
6  Gel Sample F5-6  1.196  
 AVERAGE("BATCH")  1.231  
 STDEV("BATCH")  0.073  
 STDEV("BATCH") /   
 AVERAGE("BATCH") * 100  6.892  
 
 
4 RESULTS AND DISCUSSION  
4.1 Identification of Sumatriptan Succinate by DSC 
4.1 Differential Scanning Calorimetry  
The thermogram of drug showed endotherm between 160-
200°C shows melting point of drug into the thermo gram 
though the intensity of peak is very less. 
4.2 Visual appearance and clarity 
The prepared formulations are clear and transparent. The pH 
of the formulations was found to be in the range of 6.1-6.5 as 
shown in the table no. 2. 
4.3  Rheological Studies 
The viscosity of the formulations before and after gelation 
was evaluated using Brook Field Viscometer (DV II + Pro 
Model). The results obtained are shown in table no. 3 and 
4.The result showed that viscosity of all formulations 
decreased as the shear rate increased, which indicates that 
the character of pseudoplastic fluid. The results revealed   
4.4. Gelling temperature 
Gelling temperature of all the formulations was between 34-
42ºC. 
4.5. Mucoadhesive strength 
Mucoadhesive strength was best in all samples but F5 
sample have more mucoadhessive strength  
4.6. In-vitro drug release  
The optimized formulation F5 was subjected to in-vitro drug 
release. The release study of prepared formulation was 
carried out up to 6 hrs. The result showed that formulation 
F5 showed 1.645% cumulative drug release which is greater 
than other. And its drug release was studied using different 
kinetic models. From the release study of F5, release kinetics 
was studied using zero order, First order, Higuchi release 
and Korsemeyer peppas kinetic model. The regression value 
of each of these release kinetics were calculated and 
compared. The data revealed that the release pattern of 
formulation best fitted for Zero order release kinetics as 
shown in table no. 7. In-vitro drug release study showed that 
the 1.645% was obtained for F5 in 6 hrs.  
4.7 Differential Scanning Calorimetry: The thermogram of 
drug an endothermic peak was obtained. In the thermo gram 
of formulation glass temperature of polymer is visible 
between 50- 60°C and one more endotherm between 160-
200°C shows melting point of drug into the thermo gram 
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though the intensity of peak is very less which shows the 
significant interaction between drug and polymer.  
4.8 Texture Analysis: Texture analysis report revealed that 
the after heating and conversion of sol to gel Mucoadhesive 
force (kg) obtained was 1.231 kg after 06 repetitive Gel 
sample F5.  
CONCLUSION:  
The aim of the project was to formulate the nasal in-situ gel. 
The nasal in-situ gels of Sumatriptan Succinate were 
successfully developed using poloxamer 188 and HPMC K4M 
by using cold method. The optimized concentration was 
proven to be promising nasal delivery system for anti-
migraine drug Sumariptan Succinate, which would enhance 
nasal residence time owning to increase viscosity and 
mucoadhesive strength. Further this type of delivery is 
pleasant and pain less alternative to other delivery system. 
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